Eiger BioPharmaceuticals 2017-06-30T18:30:18+00:00

IN THE NEWS
210, 2017

Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting

Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting PALO ALTO, Calif., October 2, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC, October 20 to 24, 2017.  The first abstract is from the LIMT HDV (Lambda Interferon MonoTherapy in Hepatitis Delta Virus) study and twenty-four week interim data will be [...]

1809, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors - Company Advancing Multiple Programs in Orphan Disease Pipeline PALO ALTO, Calif., September 18, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to its Board of Directors.  Dr. Loh’s clinical development and regulatory experience spans nearly two decades across all phases of development ranging from discovery to registration, [...]

509, 2017

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., Sept 5, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated interferon lambda 1a (Lambda) as a potential treatment for chronic hepatitis delta virus (HDV) infection. The mission of the FDA Office of Orphan Products Development [...]